Repligen (NASDAQ:RGEN) Rating Increased to Hold at StockNews.com

Repligen (NASDAQ:RGEN) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a report released on Wednesday.

Several other analysts have also issued reports on RGEN. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, UBS Group reduced their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Performance

Shares of NASDAQ RGEN traded up $1.88 during trading hours on Wednesday, hitting $150.47. 1,073,706 shares of the stock were exchanged, compared to its average volume of 659,834. Repligen has a one year low of $113.50 and a one year high of $211.13. The company’s 50 day moving average is $141.59 and its 200 day moving average is $144.78. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm has a market capitalization of $8.43 billion, a P/E ratio of -406.66, a P/E/G ratio of 4.27 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the company posted $0.23 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, research analysts expect that Repligen will post 1.45 EPS for the current year.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RGEN. Toronto Dominion Bank boosted its holdings in Repligen by 1.5% in the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after buying an additional 89 shares during the period. Ballentine Partners LLC boosted its holdings in Repligen by 6.2% in the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after buying an additional 105 shares during the period. Diversified Trust Co grew its holdings in Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after buying an additional 106 shares in the last quarter. Finally, CWM LLC lifted its stake in Repligen by 36.3% in the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 114 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.